Evidence map›Paper›PMID 21642951›Full record

ArticleActa pharmacologica Sinica2011

Characterization of a critical role for CFTR chloride channels in cardioprotection against ischemia/reperfusion injury.

Sunny Yang Xiang, Linda L Ye, Li-lu Marie Duan, Li-hui Liu, Zhi-dong Ge, John A Auchampach, Garrett J Gross, Dayue Darrel Duan

Open access · bronzeAbstract read
In one paragraph

Article in Acta pharmacologica Sinica, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Left ventricular and aortic dysfunction in cystic fibrosis mice.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2013
    Article
  9. Article
  10. Article
  11. Activation of volume regulated chloride channels protects myocardium from ischemia/reperfusion damage in second-window ischemic preconditioning.Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology · 2011
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Sunny Yang XiangDepartment of Pharmacology, University of Nevada School of Medicine, Reno, NV 89557, USA.
Linda L Ye
Li-lu Marie Duan
Li-hui Liu
Zhi-dong Ge
John A Auchampach
Garrett J Gross
Dayue Darrel Duan
University of Nevada, Reno · USMedical College of Wisconsin · USXiangya Hospital Central South University · CN

Funding

Signal transduction pathways regulated by cell volumeP20RR015581 · NCRR · UNIVERSITY OF NEVADA RENO · PI DUAN, DAYUE DARREL · 2000 to 2009
$19.5M
Role of Adenosine Receptors in Tissue ProtectionR01HL077707 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI AUCHAMPACH, JOHN A · 2005 to 2014
$3.4M
EFFECTS OF DRUGS UPON MYOCARDIAL HYPOXIAR01HL008311 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI GROSS, GARRETT JOHN · 1985 to 2009
$2.7M
A3 RECEPTORS--CARDIOPROTECTIVE MECHANISMSR01HL060051 · NHLBI · UNIVERSITY OF LOUISVILLE · PI AUCHAMPACH, JOHN A · 1999 to 2007
$1.3M
Physiological role of CIC-2 CI channels in heartR01HL063914 · NHLBI · UNIVERSITY OF NEVADA RENO · PI DUAN, DAYUE DARREL · 2002 to 2005
$1.0M
Novel function and mechanism of CFTR in heart failureR21HL106256 · NHLBI · UNIVERSITY OF NEVADA RENO · PI DUAN, DAYUE DARREL · 2011 to 2012
$386k
NCRR NIH HHS P20 RR015581NCRR NIH HHS P-20 RR-15581NHLBI NIH HHS HL 077707NHLBI NIH HHS HL 08311NHLBI NIH HHS HL106256NHLBI NIH HHS HL60051NHLBI NIH HHS HL63914NHLBI NIH HHS R01 HL008311NHLBI NIH HHS R01 HL060051NHLBI NIH HHS R01 HL063914NHLBI NIH HHS R01 HL077707NHLBI NIH HHS R21 HL106256
6 · The paper itself

Abstract

aimTo further characterize the functional role of cystic fibrosis transmembrane conductance regulator (CFTR) in early and late (second window) ischemic preconditioning (IPC)- and postconditioning (POC)-mediated cardioprotection against ischemia/reperfusion (I/R) injury.

methodsCFTR knockout (CFTR(-/-)) mice and age- and gender-matched wild-type (CFTR(+/+)) and heterozygous (CFTR(+/-)) mice were used. In in vivo studies, the animals were subjected to a 30-min coronary occlusion followed by a 40-min reperfusion. In ex vivo (isolate heart) studies, a 45-min global ischemia was applied. To evaluate apoptosis, the level of activated caspase 3 and TdT-mediated dUTP-X nick end labeling (TUNEL) were examined.

resultsIn the in vivo I/R models, early IPC significantly reduced the myocardial infarct size in wild-type (CFTR(+/+)) (from 40.4% ± 5.3% to 10.4% ± 2.0%, n=8, P<0.001) and heterozygous (CFTR(+/-)) littermates (from 39.4% ± 2.4% to 15.4% ± 5.1%, n=6, P<0.001) but failed to protect CFTR knockout (CFTR(-/-)) mice from I/R induced myocardial infarction (46.9% ± 6.2% vs 55.5% ± 7.8%, n=6, P>0.5). Similar results were observed in the in vivo late IPC experiments. Furthermore, in both in vivo and ex vivo I/R models, POC significantly reduced myocardial infarction in wild-type mice, but not in CFTR knockout mice. In ex vivo I/R models, targeted inactivation of CFTR gene abolished the protective effects of IPC against I/R-induced apoptosis.

conclusionThese results provide compelling evidence for a critical role for CFTR Cl(-) channels in IPC- and POC-mediated cardioprotection against I/R-induced myocardial injury.

Indexed as

Ischemic PostconditioningIschemic Preconditioning, MyocardialAnimalsApoptosisCaspase 3Cystic Fibrosis Transmembrane Conductance RegulatorDisease Models, AnimalMaleMiceMice, Inbred CFTRMice, KnockoutMyocardial Reperfusion InjuryMyocardiumPerfusionCaspase 3Cystic Fibrosis Transmembrane Conductance Regulator

Identifiers

PMID21642951
PMCPMC3217336
OpenAlexW1983196712

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.